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Introduction: In the absence of metastatic disease, surgery for syn-
chronous non–small-cell lung cancers involving multiple lobes can 
be curative. However, there currently exists no reliable prognostic 
instrument for this patient population after surgery. We undertook an 
analysis to examine the prognostic significance of adenocarcinoma 
histology and developed a prognostic nomogram.
Methods: This study was a pooled analysis of six previously reported 
datasets. Patients without extra-thoracic metastasis who underwent 
surgical resection of synchronous lung cancers in multiple lobes 
were included. Those with small cell cancer, carcinoid tumor, or 
exclusively carcinoma in situ were excluded. A multivariable Cox 
proportional hazards regression model was fitted to identify indepen-
dent survival predictors for nomogram development.
Results: Data from 467 patients were analyzed. Adenocarcinoma 
was a sole histology in 253 patients (54.2%). Those with exclusively 
adenocarcinoma histology had a better median survival than their 
counterparts: 67.4 versus 36.2 months, (p < 0.001). Multivariable 
analysis incorporating histology, sex, age, maximal T-size, highest 
N-stage, and laterality demonstrated that having exclusively adeno-
carcinoma histology independently predicted an improved survival: 
hazard ratio 0.61 (95% confidence interval: 0.48, 0.78). Other 
favorable survival predictors were N0, T-size less than or equal 
to 3 cm, bilateral cancers, age less than 70 years, and women sex. 
The developed nomogram was well calibrated and demonstrated a 
moderate to good discrimination with a bootstrap-corrected Harrell 
C-statistic of 0.70.
Conclusion: Several unique features among patients with resected 
synchronous multiple lung cancers, including the presence of exclu-
sively adenocarcinoma histology, are of prognostic significance. A 
simple nomogram incorporating these factors can be utilized to pre-
dict patient survival with acceptable accuracy.
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(J Thorac Oncol. 2015;10: 338–345)
In the United States, lung cancer is a prevalent cancer affect-ing 0.08% of population1 and as such, synchronous multiple 
lung cancers are not uncommon. Based on data from lung can-
cer screening trial, of the 484 patients with detected cancer, 35 
patients (7%) had multiple lung cancers.2 When multiple lung 
cancers are present at the same time without extra-pulmonary 
metastasis, the possibilities may include metastatic lung can-
cer to the lung or multiple primary lung cancers (MPLC). The 
treatment paradigm and prognosis of the two entities are quite 
different. Although MPLC is considered as an early stage dis-
ease, potentially curable by surgery, metastatic disease is con-
sidered incurable and surgery is rarely indicated.
A set of criteria have been developed to help differenti-
ate between the two. In 1975, Martini and Melamed proposed 
criteria using histology and interval development of multiple 
lung cancers based on 50 patients.3 MPLC can be diagnosed 
if the histological types of the cancers are different. When his-
tological types are similar, MPLC can still be diagnosed if 
the interval development of cancers is greater than 2 years 
(metachronous MPLC). Otherwise, MPLC can be diagnosed 
if there are carcinoma in situ components, without evidence of 
cancer in a common lymphatic channel, and cancers must be 
located in a different segment or lobe. It has been estimated 
that the prevalence of MPLC is approximately 2% of all 
resected lung cancers on the basis of these criteria.4 Though 
seemingly useful, the criteria are not necessarily predictive of 
survival and many multiple lung cancer patients do not receive 
surgical treatment as their overall prognosis is felt to be poor 
uniformly.5
In addition, the available staging system does not pro-
vide a reliable survival prediction for this patient population. 
The seventh edition of American Joint Committee on Cancer 
(AJCC) staging system classifies those with similar histology 
type as stage III or IV and those with different histology type as 
stage I or II6. However, it appears that histological type, whether 
similar or different, does not predict survival,7,8 whereas tumor 
size, especially the maximal tumor size and nodal involvement 
are better predictors than histology similarity.9–11 Interestingly, 
in most reports of long-term survivors after surgical resection 
of synchronous multiple lung cancers, the predominant histol-
ogy type was adenocarcinoma.12,13 From biological standpoint, 
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it is plausible that adenocarcinoma confers a better prognosis 
than other histological types. Adenocarcinoma is less strongly 
associated with cigarette smoking, which is a major cause of 
cardiovascular death.14 Furthermore, adenocarcinoma often 
arises more distally in the airway than squamous cell carci-
noma and its peripheral location may facilitate surgical resec-
tion. In addition, the incidence of adenocarcinoma histology is 
increasing among women and it is known that women gener-
ally have a longer life expectancy than men.15 Finally, unlike 
other histology types, adenocarcinoma affords a spectrum of 
diseases including the lepidic subtype which has been associ-
ated with an indolent clinical course.16
To date, although several observational studies on the 
resection of multiple lung cancers are available, it is difficult 
to summarize the results across these studies due to the differ-
ence in the inclusion criteria and baseline patient characteristics. 
In addition, no prognostic instrument has yet been introduced. 
To this end, our group sought to improve the prognostication of 
synchronous multiple non–small-cell lung cancers (NSCLC) 
by pooling our previously published, patient-level databases.8 
In this report, we test the hypothesis that adenocarcinoma is 
associated with a superior survival than other histology type. 
We update our patient follow-up status, integrate information on 
their maximal tumor size in the statistical model, and construct 
a prognostic nomogram. Because multiple lung cancers will 
become an increasingly common clinical problem, along with 
the rise in minimally invasive surgery and lung cancer screening, 
we believe that a practical prognostic instrument will be timely.
MATERIALS AND METHODS
Procurement of Database
This project has been approved by the Scientific Review 
Committee at the H. Lee Moffitt Cancer Center. The method 
of database identification and procurement has been previ-
ously detailed elsewhere.8The Medline database was searched 
for literature on surgical outcomes of multiple lung cancers 
published during 2000–2012. The first authors of publications 
containing at least 10 patients were contacted to obtain indi-
vidual-level patient database. Required variables were patient 
demography (age at surgery, sex), tumor characteristics (later-
ality, nodal stage, histological type), treatment (pneumonec-
tomy), and outcomes (overall survival time). Data on tumor 
size were available in all but one study. This database was 
updated to January 2014.
Patients and Definitions
Eligible cases were identified according to a priori inclu-
sion and exclusion criteria. Patients included in this analysis 
were those who underwent curative surgical resections (pneu-
monectomy, lobectomy, segmentectomy, or wedge resection) of 
at least two separate lung cancer foci in two lobes presenting 
synchronously, defined as cancers diagnosed simultaneously 
or within 2 years per Martini and Melamed criteria.3 Those 
with distant metastatic disease evident by imaging studies were 
excluded, along with those who only had cancers in one lobe, 
small cell carcinoma, carcinoid tumor or all non-invasive, pure 
bronchioloalveolar carcinoma, also known as adenocarcinoma 
in situ with lepedic pattern. Histology was as supplied by the 
investigators from each institution. Determination of adeno-
carcinoma status was based on morphologic examination and 
when appropriate immunohistochemical staining was per-
formed. Tumor size and nodal stage were based on pathologi-
cal examination. Patients who had cancers both unilaterally and 
bilaterally were classified as having bilateral cancers.
Statistical Analysis
Pearson’s Chi-square test and one-way analysis of vari-
ance were used to compare the difference in proportions and 
means between groups, respectively. Overall survival was cal-
culated from the date of the first surgical resection to death 
or last follow-up date. Kaplan–Meier estimator was used to 
construct survival curve and to estimate median survival. In 
univariable analysis, Log-rank test was used to compare sur-
vival across histological types. Categorization of continuous 
variables followed clinical relevance: tumor size cutoff was 
based on AJCC T-designation6 and age was dichotomized near 
the median age of patients. In multivariable analysis, Cox pro-
portional hazards regression model was fitted, incorporating 
age, sex, the largest tumor size, highest N-stage, laterality, ade-
nocarcinoma, and pneumonectomy. For regression modeling, 
missing data on tumor size was addressed by multiple imputa-
tion procedure based on Markov Chain Monte Carlo method.17 
Significance level was set at two-tailed p value less than 0.05.
Nomogram Development
A nomogram helps translate complex statistical models 
into a user-friendly graphical interface.18 The nomogram in 
this study was designed to give the probability of overall sur-
vival at 2 and 5 years. Parameter estimates obtained from the 
above Cox proportional hazards model were used to construct 
TABLE 1.  Histological Characteristics of Patients with 
Resected Synchronous Multiple Lung Cancers
Histology Type
Number of  
Patients %
One histology type present:
 Adenocarcinoma 253 54.2
 Squamous cell carcinoma 54 11.6
 Adenosquamous carcinoma 4 0.9
 Large cell carcinoma 4 0.9
 Undifferentiated or histology type other than above 3 0.6
Two histology types present
 Adenocarcinoma and squamous cell carcinoma 65 13.9
 Adenocarcinoma and large cell carcinoma 28 6.0
 Adenocarcinoma and adenosquamous cell carcinoma 12 2.5
 Adenocarcinoma and undifferentiated/other histology 14 3.0
 Squamous cell carcinoma and large cell carcinoma 11 2.4
 Squamous cell carcinoma and adenosquamous  
  cell carcinoma
6 1.3
 Squamous cell carcinoma and undifferentiated/other  
  histology
10 2.1
 Large cell carcinoma and adenosquamous cell carcinoma 3 0.6
Total 467 100.0
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nomogram scale.19 The predictive accuracy of the nomo-
gram was demonstrated by calibration and discrimination. 
Calibration was illustrated by a plot of patients with predicted 
survival (in quintile) against the actual proportion, who have 
died in each predicted quintile. The predicted survival prob-
ability for each patient was calculated using baseline hazard 
function at 2 or 5 years. Discrimination, or the ability of model 
to differentiate between patients with different prognosis, was 
demonstrated by Harrell concordance index (C-statistic), tak-
ing censored data into consideration.20 Harrell C-statistic can 
be described as the probability that a subject who has died will 
have a higher predicted probability of dying than a subject 
who is still alive and may range from 0.5 (random chance) to 
1.0 (perfectly discriminating model). Although no threshold 
exists, C-statistic between 0.70 and 0.80 is considered moder-
ate to good and 0.80 or greater is considered excellent.21 To 
reduce the bias from model over-fitting, 200 bootstrap sam-
ples with replacement were generated by computer program, 
and bootstrap-corrected Harrell C-statistic was obtained from 
full model fitted in the complete-case data set using the 0.632 
bootstrapping method.22 Analyses were conducted using SAS 
version 9.3 (SAS Institute, Cary, NC).
RESULTS
Histology Type and Patient Characteristics
Data from 467 patients were analyzed. Of these, 318 
patients (68.1%) had one histology type and 149 patients (31.9%) 
had two histology types (Table 1). No three or greater histology 
types were observed in a single patient. Adenocarcinoma was 
a sole histology for 253 patients (54.2%), and in 119 patients 
(25.5%), adenocarcinoma was present along with another his-
tology type. Overall, adenocarcinoma was the most prevalent 
histology type, observed in 374 patients (80.1%). Squamous 
cell carcinoma was the second most prevalent histology. It was 
present as a sole histology in 54 patients (11.6%) or present 
along with another histology type in 92 patients (19.7%).
Several patient characteristics were significantly associ-
ated with adenocarcinoma (Table 2). Women patients consti-
tuted 56% and 46% of cases with adenocarcinoma as a sole 
histology (all-adenocarcinoma) or adenocarcinoma along with 
another histology type (some adenocarcinoma), respectively; 
however, they constituted only 19% among cases with no 
adenocarcinoma (p < 0.001). The proportion of patients with 
small tumors (i.e., a maximal tumor size of less than or equal 
to 3 cm) was highest among those with some adenocarcinoma: 
the median maximal tumor size was 2.75 cm among patients 
with some adenocarcinoma, compared with 3.65 cm among 
those with all-adenocarcinoma and 3.45 cm among those with 
no adenocarcinoma, p value less than 0.001. In addition, the 
proportion of patients who underwent pneumonectomy was 
the lowest among cases with all-adenocarcinoma.
Survival Outcomes
At the time of analysis, there were 279 deaths. The 
median survival was 50.7 months. Among those surviving, 
TABLE 2.  Characteristics of Patients with Resected Synchronous Multiple Lung Cancers, Classified by the Number of Cancers 
with Adenocarcinoma Histology
Characteristics
Adenocarcinoma in All 
of the Cancers, 
n = 253 (%)
Adenocarcinoma with 
Another Histology Type,
n = 119 (%)
Adenocarcinoma in 
None of the Cancers,
n = 95 (%)
Total,
n = 467 (%) p value
Sex <0.001
 Men 110 (44) 67 (56) 77 (81) 254 (54)
 Women 143 (56) 52 (44) 18 (19) 213 (46)
Age 0.79
 <70 years 138 (54) 62 (52) 54 (57) 254 (54)
 ≥70 years 115 (46) 57 (48) 41 (43) 213 (46)
Maximal T sizea <0.001
 ≤3 cm 136 (60) 44 (48) 27 (33) 207 (52)
 >3–5 cm 67 (29) 30 (33) 36 (45) 133 (33)
 >5 cm 25 (11) 17 (19) 18 (22) 60 (15)
Highest N-stage 0.06
 N0 184 (73) 81 (68) 60 (63) 325 (70)
 N1 31 (12) 14 (12) 22 (23) 67 (14)
 N2 38 (15) 24 (20) 13 (14) 75 (16)
Laterality 0.27
 Unilateral 128 (51) 68 (57) 44 (46) 240 (51)
 Bilateral 125 (49) 51 (43) 51 (54) 227 (49)
Pneumonectomy <0.001
 Yes 17 (7) 16 (13) 24 (25) 57 (12)
 No 236 (93) 103 (87) 71 (75) 410 (88)
aData available from 400 patients.
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the median follow-up time was 51.5 months. Death within 30 
days of surgery was observed in nine patients (1.9 %). When 
classifying patients by the number of cancers with adenocarci-
noma histology, those with all-adenocarcinoma histology had 
the best median overall survival of all patient groups (Fig. 1A). 
The median survival among patients with all-adenocarcinoma 
histology was 67.4 months, compared with 39.4 months and 
30.4 months among those with some adenocarcinoma and no 
adenocarcinoma, respectively (p < 0.001). When considering 
the status of adenocarcinoma as a binary variable, patients 
with all-adenocarcinoma histology had a median survival of 
67.4 months, compared with the rest of the patients who had a 
median survival of 36.2 months (p < 0.001; Fig. 1B).
Multivariable Analysis
We performed a multivariable analysis, taking into 
account the differences in patient characteristics between 
those with exclusively adenocarcinoma and the remainders. 
First, we examined all variables in a univariable analysis. 
Sex, age, maximal T-size, highest N-stage, laterality, and his-
tology were significantly associated with survival (Table 3). 
Pneumonectomy was also associated with survival, albeit of 
marginal significance. However, no significant survival differ-
ence by institution or by tumor count was found. Second, we 
performed multivariable analysis, incorporating all significant 
or marginally significant variables. This analysis indicated that 
pneumonectomy was not an independent predictor of survival. 
In the final model, six significant variables were retained. In 
the order of strength of association, these variables were high-
est N-stage, maximal T-size, laterality, age, sex, and adenocar-
cinoma histology.
To examine whether the above findings would remain 
robust despite a change in the definition of cancer synchronic-
ity, a sensitivity analysis was performed by excluding patients 
who had the interval between their surgical resections greater 
than 6 months (n = 42). In this subgroup, the median survival 
FIGURE 1. A, Kaplan–Meier survival estimates 
of patients, stratified by the number of cancers 
with adenocarcinoma histology. B, Kaplan–
Meier survival estimates of patients, stratified by 
the presence of adenocarcinoma histology in all 
of the cancers
342 Copyright © 2014 by the International Association for the Study of Lung Cancer
Tanvetyanon et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015
was 49.9 months. Not having exclusively adenocarcinoma his-
tology was still independently associated with an increased 
mortality, hazard ration (HR): 1.50 (95% confidence interval 
[CI]: 1.15, 1.96). Moreover, there was no substantial change 
in the hazard ratio estimates for other variables and the order 
of strength of association remained unchanged.
Nomogram and its Predictive Accuracy
Based on the identified independent survival predic-
tors, a prognostic nomogram estimating the probability of 
survival at 2 and 5 years after surgery was developed (Fig. 2). 
N-stage emerged as the strongest survival predictor: N2 was 
assigned 100 points. Having all-adenocarcinoma histology 
was assigned 51 points. The total point derived from this 
nomogram may range from 0 to 431 points, corresponding to 
the predicted 2-year survival probability of approximately 90 
and 10%, respectively, and the predicted 5-year survival prob-
ability of approximately 80 and 1%, respectively.
The resultant nomogram calibrated well. A plot of the 
predicted survival probability against the actual proportion 
surviving indicated an expected linear correlation. In accor-
dance with the model scope, no survivor was observed in 
the highest predicted 5-year survival probability quintile at 
the time of analysis (80–100% 5-year survival probability; 
Fig. 3A). No death was yet observed in the lowest predicted 
2-year survival probability quintile at the time of analysis 
(0–20% 2-year survival probability; Fig. 3B). The nomogram 
demonstrated a good discrimination based on the full model, 
with Harrell C-statistic of 0.713. An internal validation based 
on 200 computer-generated bootstrap samples yielded an opti-
mism-adjusted Harrell C-statistic of 0.704.
DISCUSSION
In this report, we performed a pooled analysis of data 
obtained from 467 patients who underwent surgery for syn-
chronous multiple lung cancers located in multiple lobes. We 
found that histology was of prognostic significance in that 
patients with exclusively adenocarcinoma histology had a 
better prognosis than others. Those with all-adenocarcinoma 
histology, which comprised 54.2% of patients in the study, 
TABLE 3.  Predictors of Survival After Surgery for Synchronous Multiple Lung Cancers
Variables
Univariable
HR (95% CI) p value
Multivariable
HR (95% CI)
Adjusted
p-value
Sex
 Men 1.63 (1.28, 2.08) <0.001 1.52 (1.18, 1.97) 0.001
 Women Reference Reference
Age
 >70 years 1.37 (1.08, 1.73) 0.009 1.59 (1.24, 2.02) <0.001
 ≤70 years Reference Reference
Maximal T size
 >5 cm 2.05 (1.44, 2.92) <0.001 1.90 (1.24, 2.90) 0.004
 3 to 5 cm 1.51 (1.14, 1.99) 0.004 1.27 (0.95, 1.70) 0.11
 ≤3 cm Reference Reference
Highest N-stage
 N2 1.98 (1.46, 2.67) <0.001 2.14 (1.56, 2.92) <0.001
 N1 1.63 (1.17, 2.28) 0.004 1.71 (1.22, 2.42) 0.002
 N0 Reference Reference
Laterality
 Unilateral 1.64 (1.29, 2.08) <0.001 1.83 (1.43, 2.34) <0.001
 Bilateral Reference Reference
Histology
 Not all-adenocarcinoma 1.64 (1.29, 2.07) <0.001 1.47 (1.15, 1.89) 0.002
 All-adenocarcinoma Reference Reference
Pneumonectomy
 Yes 1.40 (0.99, 1.98) 0.06 - -
 No Reference
Number of tumorsa:
2 0.85 (0.57, 1.26) 0.41 - -
>2 Reference
Institution
 Site(s) 0.85–1.67 0.16–0.99 - -
 Reference site Reference
aData available from 270 patients
HR, hazard ratio; CI, confidence interval limits.
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experienced a 32% reduction in the risk of overall mortal-
ity. In addition, women sex, younger age, smaller tumor size, 
lack of nodal involvement, and bilateral cancers were good 
prognostic features. A nomogram predicting the probability 
of survival based on these factors calibrated well and demon-
strated a moderate to good measure of discrimination.
FIGURE 2.  Nomogram estimating the probability of 2- and 5-year survival among patients who underwent surgical resection of 
synchronous multiple lung cancers: (To use the nomogram, calculate a total point by adding points associated with all observed risk 
factors [N1 = 71 points, N2 = 100 points, largest T-size greater than 5 cm = 84 points, largest T-size between over 3 cm up to 5 = 31 
points, unilateral disease = 79 points, age greater than 70 years = 61 points, men sex = 56 points, histology not all-adenocarcinoma 
= 51 points] and draw a vertical line downward from the total point line to read a predicted 2- and 5-year survival probability.)
FIGURE 3. A, Box plot of the predicted 5-year survival probability plotted against the actual observed survival (box inter-quar-
tile range; whisker range). B, Box plot of the predicted 2-year survival probability plotted against the actual observed survival 
(box inter-quartile range; whisker range).
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The prognostic value of age, sex, tumor size, and nodal 
stage is not unexpected. In addition, the survival advantage of 
patients with bilateral cancers, compared with those with uni-
lateral cancers, has been previously proposed to have resulted 
from a more complete exclusion of cases with systemic meta-
static disease.8 What could now explain the favorable survival 
associated with all-adenocarcinoma histology?
This association is notably independent from age, sex, 
tumor size, nodal stage, and cancer laterality. The absence of 
dose–response relationship, i.e., patients with some, but not 
all, adenocarcinoma do not seem to have a better survival than 
those with no adenocarcinoma, points to a unique biological 
characteristic of disease with all-adenocarcinoma histology. 
Data from studies of patients with single, early stage lung can-
cer who undergo surgical resection do not necessarily show 
that adenocarcinoma is associated with a better prognosis after 
surgery than other NSCLC histology types.23,24 Nevertheless, 
it is widely accepted that there exist some minimally invasive 
or in-situ adenocarcinomas which confer an excellent progno-
sis after surgery.16,25 These tumors have a tendency to exhibit 
an aerogenous or lepidic spreading pattern, often resulting in 
a multifocal disease.26 Perhaps the observed favorable sur-
vival of patients with exclusively adenocarcinoma histology 
in our study is driven by the high proportion of patients with 
minimally invasive adenocarcinoma component, even though 
we have excluded patients with exclusively in-situ carcinoma 
from analysis. Although studies have estimated the prevalence 
of minimally invasive adenocarcinoma in resected single lung 
cancer ranging from 5 to 20%,27,28 the prevalence could be 
higher in our study which only includes multiple lung cancers.
To the best of our knowledge, this article presents the 
first prognostic instrument specific for patients with resected 
multiple lung cancers. For patients with single lung cancer, 
several prognostic factors apart from AJCC stage have been 
identified, including tumor grade,29,30 peripheral location,30 
lymphovascular invasion,23 age over 70 years,31 and pulmo-
nary function test.31 Our proposed nomogram does not include 
variables such as tumor grade, lymphovascular invasion or 
subtype of adenocarcinoma. Although additional informa-
tion may further improve the predictive performance of the 
nomogram, some pathological variables may not be available 
pre-operatively. Another important caveat to our nomogram is 
that it was derived from a highly select population in the era 
when many patients with synchronous multiple lung cancers 
were not offered surgical resections. This selection bias could 
result in the nomogram providing an overly optimistic esti-
mate of survival probability. However, keeping in mind the 
direction of this bias, the nomogram can still be useful for 
clinical decision making. For instance, it can be stated that a 
patient who has accumulated approximately 300 total points 
will have approximately 10% probability of survival at 5 years 
by an optimistic estimate.
There are other limitations in our study. We were unable 
to re-examine the histology type. It is possible that some 
patients with adenocarcinoma were misclassified as not hav-
ing adenocarcinoma, thus diluting the true strength of asso-
ciation between having all-adenocarcinoma histology and 
survival. However, this misclassification was mitigated by the 
large specimen size typically obtained from lung resection 
for histological examination.32 In addition, we were unable to 
obtain data on adjuvant chemotherapy or radiation treatment, 
although many patients were treated before adjuvant therapy 
era and its impact on survival is modest, affecting across all 
histological groups. For instance, adjuvant chemotherapy 
for selected patients with NSCLC has been associated with 
an absolute increase in survival of 4% at 5 years regardless 
of histology type.33 Although in our analysis, we intend to 
exclude patients with distant metastatic disease, a number of 
patients with undiagnosed metastatic disease may have been 
included because a staging Positron Emission Tomography 
scan, which is recommended pre-operatively nowadays,34 was 
not routinely performed back then. Nonetheless, based on the 
observed overall survival which is much better than those typ-
ical for metastatic lung cancer, the number of such patients is 
probably small. Finally, tumor size was measured from patho-
logical examination which may be different from radiological 
measurement, especially low grade tumors which often seem 
smaller than they really are.35 Although the internal valida-
tion of the nomogram showed a satisfactory performance, we 
are missing important information, thus an external validation 
will be necessary to confirm its validity across populations.
In summary, several unique characteristics of patients 
who present with multiple NSCLC can be used to predict 
survival after surgical resections. Having an exclusively ade-
nocarcinoma histology portends a good prognosis. This infor-
mation may be useful for clinical decision making and for 
hypothesis generating in future study.
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